This study is the first to our knowledge to establish an association between diminished expression of CDK12/13 and heightened STING activity, identifying CDK12/13 expression as a predictive biomarker for ICB response and patient survival in ICB-treated cohorts in a pan-cancer context. This evidence concerns the gene STING1 and cancer.